Drug intelligence / Profile preview

DA-4701

Development stage: Preclinical
Lead developer: Dong-A ST
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

DA-4701 is a preclinical-stage oncology drug candidate being developed by Dong-A ST. It utilizes targeted protein degradation (TPD) technology, likely as a proteolysis-targeting chimera (PROTAC) or molecular glue, to selectively degrade a specific protein involved in cancer progression. While the exact molecular target remains undisclosed, the asset is part of Dong-A ST's strategic focus on expanding its oncology portfolio through novel modalities that can address previously undruggable targets.

Beyond the preview

Go deeper on DA-4701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-4701.

Explore the full profile